AstraZeneca Shares Slide 7% on Bristol Myers Merger Talks Reports

AZN shares fell as much as 7% on August 3, 2026 after the Financial Times reported the company had held preliminary talks with BMY about a combination that could create a pharmaceutical company worth close to $400 billion in combined value. Because AstraZeneca is one of the largest constituents of the FTSE 100, the decline weighed directly on the index, pulling it lower for the session.

AstraZeneca's selloff stands in contrast to Bristol Myers Squibb's roughly 6% gain in U.S. premarket trading on the same report, a divergence that signals investors see this as more of a rescue for BMY's weaker growth outlook than a value-accretive deal for AstraZeneca. Neither company has confirmed the talks: AstraZeneca declined to comment and Bristol Myers Squibb did not respond to media inquiries.

The drop also reflects real deal-execution risk beyond investor sentiment. Oncology represents more than 40% of Bristol Myers Squibb's first-half 2026 sales, and the companies' cancer immunotherapy franchises compete head-to-head, which raises the odds of prolonged antitrust review or forced divestitures if talks advance to a formal deal. Analysts have described themselves as caught off guard by the idea of AstraZeneca, the stronger-growth company of the two, pursuing a merger of this kind.

What to watch: any formal statement from AstraZeneca's board, follow-through (or denial) from Bristol Myers Squibb, and whether AstraZeneca's share-price weakness persists or reverses once more details emerge.

Related Stocks

• AZN
• BMY